What this means
This registered trial was set up to test whether the diabetes drug metformin can prevent frailty. The text describes a plan and goal, not any results.
Plain-English summary written by an AI model from the registry listing.
- Status
- Completed
- Who can join
- Ages 65–90
- Where
- 1 site, including Texas
The science
- Registered title
- Metformin for Preventing Frailty in High-risk Older Adults
- Trial ID
- NCT02570672 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Frailty
- What is tested
- Metformin, Placebo
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Ages
- 65 Years to 90 Years
- Dates
- First posted Oct 7, 2015 · updated Oct 15, 2026
Registry summary
Frailty is a geriatric syndrome which leads to poor health outcomes in older adults, such as falls, disability, hospitalization, institutionalization, and death. Due to the dramatic growth in the U.S. aging population and the health care costs associated with frailty (estimated at more than $18 billion per year), frailty is a major health care problem. There has been little research into potential pharmacologic interventions that would delay or reduce the incidence of frailty. Thus, the major goal of this study is to test metformin as a novel intervention for the prevention of frailty. The investigators propose that diabetes/insulin resistance and inflammation are major contributors to frailty, and that the use of metformin to modulate diabetes/insulin resistance and inflammation will prevent and/or ameliorate the progression of frailty.
Sites (1)
- University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States